Recombinant Human Erythropoietin Injection Market to Reach USD 10.2 Billion by 2032 | CAGR 3.8% https://www.24lifesciences.com/recombinant-human-erythropoietin-injection-market-14067 #RecombinantErythropoietin #Biopharmaceuticals #AnemiaTreatment #ChronicKidneyDisease #OncologyTherapies #Hematology #BiologicsMarket #HealthcareInnovation #PharmaMarket #24LifeSciences

Hydroxycarbamide Market’s CAGR of 6.1%: Leaders in Oncology & Hematology According to a newly published market research report by 24LifeSciences, global hydroxycarbamide market was valued at USD 226 million in 2025 and is projected to grow from USD 240 million in 2026 to reach USD 338 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Hydroxycarbamide, clinically known as hydroxyurea, is a foundational antineoplastic and antimetabolite medication that functions by inhibiting ribonucleotide reductase, a crucial enzyme for DNA synthesis. This mechanism positions it as a cornerstone therapy for several hematologic conditions. Its primary applications include the management of sickle cell disease, where it significantly reduces the frequency of painful crises and acute chest syndrome, as well as the treatment of specific cancers like chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Its established efficacy in cytoreduction and symptom management continues to underpin its critical importance in hematology and oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/663/hydroxycarbamide-market-market